Clinical trialNCT05529654Active, not recruitingInterventional

IMpella-Protected cArdiaC Surgery Trial (IMPACT)

SponsorAbiomed Inc.Enrollment100Left Ventricular Dysfunction

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel Goldstein, MD
Montefiore Medical Center
Principal Investigator
clinicaltrials.gov ↗
Edward Soltesz, MD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗
Hermann Reichenspurner, MD, PhD
University Heart & Vascular Center Hamburg
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Cardiology Associates Research Group
Jonesboro, Arkansas, United States
Keck School of Medicine
Los Angeles, California, United States
Tri-City Medical Center
San Diego, California, United States
Nch Rooney Heart Institute
Naples, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Brigham & Women'S
Boston, Massachusetts, United States
Mass General Hospital
Boston, Massachusetts, United States
Minneapolis Heart Institute Foundation/abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Barnes-Jewish Hospital
St Louis, Missouri, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Nyu Langone Health
New York, New York, United States
New York- Presbyterian Hospital/ Columbia University Medical Center
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
New Hanover Regional Medical Center
Wilmington, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Providence St. Vincent Medical Center
Portland, Oregon, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Centennial Heart Cardiovascular
Nashville, Tennessee, United States
University of Texas Austin Dell Medical School/ascension Texas
Austin, Texas, United States
Baylor Scott and White - Plano
Plano, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Sept 2023
Primary completion: 4 Nov 2025
Completion: 31 Jul 2026
Last update posted: 12 May 2026
Registered enrollment: 100
Registry id: NCT05529654

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.